Xilio Therapeutics
29 hedge funds and large institutions have $48.3M invested in Xilio Therapeutics in 2022 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 3 increasing their positions, 9 reducing their positions, and 6 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0.33% less ownership
Funds ownership: 4.65% → 4.32% (-0.33%)
7% less capital invested
Capital invested by funds: $52.2M → $48.3M (-$3.89M)
9% less funds holding
Funds holding: 32 → 29 (-3)
50% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 6
67% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OCA
Octagon Capital Advisors
New York
|
+$6.73M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.31M |
| 3 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$211K |
| 4 |
CC
Cannell Capital
Alta,
Wyoming
|
+$34.6K |
| 5 |
NL
NWAM LLC
Mercer Island,
Washington
|
+$27.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
-$6.07M |
| 2 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$4.82M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$836K |
| 4 |
Norges Bank
Oslo,
Norway
|
-$356K |
| 5 |
Renaissance Technologies
New York
|
-$130K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
JP Morgan Chase
New York
| $8K | -$78 | -2 | -1% |
|
|
TRCT
27
Tower Research Capital (TRC)
New York
| $6K | -$11.3K | -292 | -66% |
|
28
UBS Group
Zurich,
Switzerland
| $1K | -$7.26K | -187 | -93% |
|
|
DM
29
Deerfield Management
New York
| – | -$6.07M | -148,478 | Closed |
|
|
RCM
30
RA Capital Management
Boston,
Massachusetts
| – | -$4.82M | -117,837 | Closed |
|
|
31
Norges Bank
Oslo,
Norway
| – | -$356K | -8,706 | Closed |
|
|
B
32
Bailard
Foster City,
California
| – | -$107K | -2,617 | Closed |
|
33
Wells Fargo
San Francisco,
California
| – | +$39 | +1 | +25% |
|
XLO Hedge Fund Activity: Q3 2022 in Review
29 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in Xilio Therapeutics (XLO) for Q3 2022, worth a combined $48.3M — down 7.4% from $52.2M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of XLO and 3 opened new positions — a net loss of 3 holders — while 9 trimmed existing stakes and 3 added.
The largest buyer was Octagon Capital Advisors, opening a new position worth an estimated $6.73M. The largest seller was Deerfield Management, exiting entirely with an estimated $6.07M sold.
- 29 institutional investors held Xilio Therapeutics (XLO) as of Q3 2022, down from 32 in Q2 2022.
- Funds reported $48.3M of Xilio Therapeutics stock for Q3 2022, down 7.4% quarter-over-quarter.
- 3 funds opened new Xilio Therapeutics positions in Q3 2022 and 6 closed out, a net change of -3 holders.
- The largest Xilio Therapeutics buyer in Q3 2022 was Octagon Capital Advisors, an estimated $6.73M added.
- The largest Xilio Therapeutics seller in Q3 2022 was Deerfield Management, an estimated $6.07M sold.
Based on aggregated 13F filings for Q3 2022.